Hypera S.A. (HYPMY)
OTCMKTS
· Delayed Price · Currency is USD
5.07
+0.05 (0.95%)
Jul 3, 2025, 10:32 AM EDT
Hypera Revenue
Hypera had revenue of 1.08B BRL in the quarter ending March 31, 2025, a decrease of -40.83%. This brings the company's revenue in the last twelve months to 6.70B, down -16.74% year-over-year. In the year 2024, Hypera had annual revenue of 7.44B, down -5.97%.
Revenue (ttm)
6.70B BRL
Revenue Growth
-16.74%
P/S Ratio
2.73
Revenue / Employee
638.94K BRL
Employees
10,481
Market Cap
3.19B USD
Revenue Chart
* This company reports financials in BRL.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.44B | -472.19M | -5.97% |
| Dec 31, 2023 | 7.91B | 368.30M | 4.88% |
| Dec 31, 2022 | 7.55B | 1.61B | 27.10% |
| Dec 31, 2021 | 5.94B | 1.85B | 45.21% |
| Dec 31, 2020 | 4.09B | 794.12M | 24.10% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Elite Pharmaceuticals | 84.04M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
Hypera News
- 3 months ago - Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 months ago - Hypera: Short-Term Pain For Long-Term Gain - Seeking Alpha
- 5 years ago - Hypera S.A.: Adding The Brazilian Pharma To Your Portfolio - Seeking Alpha
- 5 years ago - A Brazilian-Focused Dividend Portfolio - Seeking Alpha